You are here

Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-12-C-0183
Agency Tracking Number: A2-5435
Amount: $749,505.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: A12a-T027
Solicitation Number: 2012.1
Solicitation Year: 2012
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-09-30
Award End Date (Contract End Date): 2016-03-01
Small Business Information
2213 Evening Sun Road
Nazareth, PA 18064
United States
DUNS: 000000000
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Garry Morefield
 (610) 573-9620
Business Contact
 Garry Morefield
Title: Dr.
Phone: (610) 573-9620
Research Institution
 Purdue University
 Harm HogenEsch
624 Harrison Street
West Lafayette, IN 47907
United States

 (765) 496-3487
 Nonprofit College or University

A vaccine to protect against diseases resulting from infection with Streptococcus pyogenes is under development. This vaccine utilizes a recombinant fusion protein (SpeAB) comprising of genetically detoxified SpeA, a secreted toxin, and SpeB, a surface bound and secreted cysteine protease. During phase I investigations a lead vaccine formulation was determined by optimization of critical parameters such as buffer, pH, stabilizer, and adjuvant interactions. Potency studies in mice demonstrated significantly greater induction of an antigen-specific IgG immune response to the vaccine than antigen alone. Additionally, the antibodies produced were functional at neutralization of wild type SpeA toxin. These results demonstrate that the SpeAB vaccine developed during the phase I investigation has great potential to provide protection against diseases resulting from infection by Streptococcus pyogenes. For phase II development of the vaccine the overall goal is to complete non-clinical safety studies in preparation of movement into clinical trials. To achieve this goal technical objectives including optimization of assays for antigen characterization, stability, and potency, development of cGMP scalable processes for fermentation and purification of SpeAB, and correlation of SpeAB potency with formulation stability will be investigated.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government